tert-butyl 4-{[4-methyl-3,6-dioxo-2-phenyl-5-(pyridin-3-ylmethyl)-2,3,5,6-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]carbonyl}piperidine-1-carboxylate | 1217897-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl 4-{[4-methyl-3,6-dioxo-2-phenyl-5-(pyridin-3-ylmethyl)-2,3,5,6-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]carbonyl}piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-[4-methyl-3,6-dioxo-2-phenyl-5-(pyridin-3-ylmethyl)pyrazolo[4,3-c]pyridine-1-carbonyl]piperidine-1-carboxylate
• CAS: 1217897-93-2
• 化学式: C₃₀H₃₃N₅O₅
• 分子量: 543.623
• InChiKey: TUDKCNWWHIMULY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  40
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  103
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
  申请人：GENKYO TEX SA

  公开号：EP2166008A1

  公开（公告）日：2010-03-24

  The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式(I)的吡唑吡啶衍生物，其药物组合物以及它们用于治疗和/或预防与烟酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）相关的疾病或症状。
• PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS
  申请人：Page Patrick

  公开号：US20110172266A1

  公开（公告）日：2011-07-14

  The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式（I）的吡唑吡啶衍生物，其药物组成物，以及它们用于治疗和/或预防与尼克酰胺腺嘌呤二核苷酸磷酸酰化酶（NADPH氧化酶）相关的疾病或病症的用途。
• METHODS OF PRESERVING AND PROTECTING PANCREATIC BETA CELLS AND TREATING OR PREVENTING DIABETES BY INHIBITING NOX-1
  申请人：EASTERN VIRGINIA MEDICAL SCHOOL

  公开号：US20160010061A1

  公开（公告）日：2016-01-14

  Methods of preserving and/or protecting pancreatic beta cells by inhibiting NOX-1. In a further aspect, NOX-1 inhibitors are administered to a subject in order to preserve and/or protect beta cells in the prevention or treatment of diabetes. NOX-1 inhibitors are also disclosed; The method can be used to preserve beta cell/islet survival in vitro, or in vivo in cells exposed to stressful stimuli including but not limited to inflammation, inflammatory cytokines, high glucose, or elevated free fatty acids.
• US8481562B2
  申请人：——

  公开号：US8481562B2

  公开（公告）日：2013-07-09
• US8940760B2
  申请人：——

  公开号：US8940760B2

  公开（公告）日：2015-01-27